A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice - PubMed (original) (raw)

. 2002 Jun;160(6):2295-307.

doi: 10.1016/S0002-9440(10)61177-7.

Susan Guillet, Elizabeth Tomlinson, Kenneth Hillan, Barbara Wright, Gretchen D Frantz, Thinh A Pham, Lisa Dillard-Telm, Siao Ping Tsai, Jean-Philippe Stephan, Jeremy Stinson, Timothy Stewart, Dorothy M French

Affiliations

A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice

Katrina Nicholes et al. Am J Pathol. 2002 Jun.

Abstract

Most mouse models of hepatocellular carcinoma have expressed growth factors and oncogenes under the control of a liver-specific promoter. In contrast, we describe here the formation of liver tumors in transgenic mice overexpressing human fibroblast growth factor 19 (FGF19) in skeletal muscle. FGF19 transgenic mice had elevated hepatic alpha-fetoprotein mRNA as early as 2 months of age, and hepatocellular carcinomas were evident by 10 months of age. Increased proliferation of pericentral hepatocytes was demonstrated by 5-bromo-2'-deoxyuridine incorporation in the FGF19 transgenic mice before tumor formation and in nontransgenic mice injected with recombinant FGF19 protein. Areas of small cell dysplasia were initially evident pericentrally, and dysplastic/neoplastic foci throughout the hepatic lobule were glutamine synthetase-positive, suggestive of a pericentral origin. Consistent with chronic activation of the Wingless/Wnt pathway, 44% of the hepatocellular tumors from FGF19 transgenic mice had nuclear staining for beta-catenin. Sequencing of the tumor DNA encoding beta-catenin revealed point mutations that resulted in amino acid substitutions. These findings suggest a previously unknown role for FGF19 in hepatocellular carcinomas.

PubMed Disclaimer

Figures

Figure 1.

Figure 1.

Preneoplastic hepatocellular changes in FGF19 transgenic mice. As early as 14 weeks of age pericentral hepatocytes formed a dense cluster around the central veins (arrows) with polarization of nuclei of the innermost hepatocytes away from the vessel lumen in FGF19 transgenics (A) that was not present in liver from nontransgenic littermate mice (B). Pericentral small dysplastic hepatocytes (C) were the predominant type of hepatocellular dysplasia although foci of large dysplastic hepatocytes (D) were occasionally noted. Arrows delineate areas of altered hepatocellular foci (shown at higher magnification in the insets). Original magnifications: ×100 (A and B); ×400 (C and D). Inset original magnifications: ×400 (A and B); ×600 (C and D).

Figure 2.

Figure 2.

Hepatocellular neoplasia in FGF19 transgenic mice. A: Multiple, large, raised tumors protrude from the hepatic surface of the liver from a 10-month-old FGF19 transgenic mouse (arrows). B: Histologically, neoplastic cells invade and replace normal hepatic architecture and are arranged in solid sheets or cords. Arrows mark the border of the tumor and adjacent normal liver. C: Pleomorphism of neoplastic hepatocytes and atypical mitotic figures (arrows). Original magnifications: ×40 (B); ×400 (C).

Figure 3.

Figure 3.

FGFR4 expression in murine liver. Bright-field (A) and dark-field (B) illumination of in situ hybridization with a murine FGFR4 riboprobe showing expression in perivenular and random hepatocytes. C and D: Higher magnification of bright-field demonstrating silver grains over random small hepatocytes. Original magnifications: ×100 (A and B); ×400 (C and D).

Figure 4.

Figure 4.

Increased proliferation of pericentral hepatocytes in FGF19 transgenics. Immunostaining for BrdU after a 5-day infusion by osmotic minipump of liver from a wild-type (A) and a FGF19 transgenic mouse (B). Morphometric analysis of BrdU-immunostained sections from FGF19 transgenics compared to wild-type mice: 2 to 4 months (C), 7 to 9 months (D), and FGF19-injected mice (E). The labeling index denotes the number of BrdU-positive hepatocytes divided by the total number of cells counted and indicated as a percentage. *, P < 0.05. Original magnifications: ×200 (A and B); ×600 (inset in B).

Figure 5.

Figure 5.

Glutamine synthetase immunoreactivity of dysplastic and neoplastic hepatocytes from FGF19 transgenics. A: Neoplastic cells are strongly glutamine synthetase-positive. B: Liver from a wild-type mouse showing normal perivenular glutamine synthetase immunostaining. C: Dysplastic hepatocytes are strongly glutamine synthetase-positive. D: Normal glutamine synthetase immunoreactivity of perivenular hepatocytes. Original magnifications: ×40 (A and B); ×400 (C and D).

Figure 6.

Figure 6.

Expression of AFP by neoplastic and dysplastic hepatocytes. Increased expression of AFP mRNA in FGF19 transgenic liver compared to wild-type liver at 2 to 4 months of age (A) and 7 to 9 months of age (B). *, P < 0.05. Bright-field (C) and dark-field (D) illumination of in situ hybridization with AFP riboprobe showing expression of AFP by pericentral dysplastic hepatocytes (arrows). Bright-field (E) and dark-field (F) illumination of in situ hybridization with AFP riboprobe showing expression of AFP by neoplastic hepatocytes (arrows). Original magnifications, ×100.

Figure 7.

Figure 7.

β-Catenin immunoreactivity of neoplastic hepatocytes from FGF19 transgenics. A: Strong nuclear staining of neoplastic cells compared with surrounding liver. Arrows mark the border of the tumor and adjacent normal liver. B: Neoplastic hepatocytes with nuclear immunoreactivity for β-catenin. C: Amino acid sequence alignment of the N-terminal region of β-catenin from wild-type (top) and mutant clones with amino acid substitutions (bold) in and adjacent to the GSK-3B phosphorylation domain (red). D: Sequencing data for DNA from normal liver and HCC with nucleotide substitutions at codon 34 (shaded). Original magnifications: ×200 (A); ×400 (B).

Similar articles

Cited by

References

    1. Ornitz DM, Itoh N: Fibroblast growth factors. Genome Biol 2001, 2:3005.1-3005.12 - PMC - PubMed
    1. Marsh SK, Bansal GS, Zammit C, Barnard R, Coope R, Roberts-Clarke D, Gomm JJ, Coombes RC, Johnston CL: Increased expression of fibroblast growth factor 8 in human breast cancer. Oncogene 1999, 18:1053-1060 - PubMed
    1. Mattila MM, Ruohola JK, Valve EM, Tasanen MJ, Seppanen JA, Harkonen PL: FGF-8b increases angiogenic capacity and tumor growth of androgen-regulated S115 breast cancer cells. Oncogene 2001, 20:2791-2804 - PubMed
    1. Ruohola JK, Viitanen TP, Valve EM, Seppanen JA, Loponen NT, Keskitalo JJ, Lakkakorpi PT, Harkonen PL: Enhanced invasion and tumor growth of fibroblast growth factor 8b-overexpressing MCF-7 human breast cancer cells. Cancer Res 2001, 61:4229-4237 - PubMed
    1. Valve EM, Nevalainen MT, Nurmi MJ, Laato MK, Martikainen PM, Harkonen PL: Increased expression of FGF-8 isoforms and FGF receptors in human premalignant prostatic intraepithelial neoplasia lesions and prostate cancer. Lab Invest 2001, 81:815-826 - PubMed

MeSH terms

Substances

LinkOut - more resources